Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Higher Naloxone Doses Narrowly Favored By FDA Panel

Executive Summary

Divided advisory committee concludes the current naloxone approval standard is inadequate due in part to increase in overdoses from powerful synthetic opioids, but doesn't offer FDA a clear alternative.

Advertisement

Related Content

Will Primatene Mist Inventory Ever Leave The Warehouse?
Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns
Unapproved Petitioner: Clinical-Stage Firm Wants FDA Scrutiny Of Naloxone Formulations
FDA’s Opioid Crisis Response: More Pressure For Treatment Drugs
Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
Recent And Upcoming FDA Advisory Committees
FDA’s Naloxone Product Approval Standards May See Changes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel